Antibody mimicry, receptors and clinical applications

Human Antibodies

Volumn 25, Issue 3-4, 2017, Pages 75-85

  Horenstein, Alberto L ^a,b   Chillemi, Antonella ^a,b   Quarona, Valeria ^a,b   Zito, Andrea ^a,b   Mariani, Valentina ^a,b   Faini, Angelo C ^a,b   Morandi, Fabio ^c   Schiavoni, Ilaria ^d   Ausiello, Clara Maria ^d   Malavasi, Fabio ^a,b,e  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c G GASLINI INSTITUTE   (Italy)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^e CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

Author keywords

Agonistic; Allosteric; Antagonistic; Anti CD38 antibodies; Biespecific; Monoclonal antibodies

Indexed keywords

CD137 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CD8 ANTIGEN; CELL SURFACE RECEPTOR; CYTOKINE; DARATUMUMAB; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 2; INTERLEUKIN 6; LIGAND; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR; ADP RIBOSYL CYCLASE/CYCLIC ADP RIBOSE HYDROLASE 1; CYCLIC ADENOSINE DIPHOSPHATE RIBOSE; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOLOGIC FACTOR; LYMPHOCYTE ANTIGEN RECEPTOR; PROTEIN BINDING;

ALLOSTERISM; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; CALCIUM HOMEOSTASIS; CELL ACTIVATION; CELL PROLIFERATION; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; LIGAND BINDING; MOLECULAR MIMICRY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; ANTIBODY SPECIFICITY; CYTOLOGY; GENETICS; IMMUNOLOGY; METABOLISM; NEOPLASM; PATHOLOGY; RECEPTOR CROSS-TALK; T LYMPHOCYTE;

ADP-RIBOSYL CYCLASE 1; ALLOSTERIC REGULATION; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CYCLIC ADP-RIBOSE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOLOGIC FACTORS; LIGANDS; MOLECULAR MIMICRY; NEOPLASMS; PROTEIN BINDING; RECEPTOR CROSS-TALK; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 85018419990     PISSN: 10932607     EISSN: 1875869X     Source Type: Journal    
DOI: 10.3233/HAB-160305     Document Type: Review

References (79)

1. M. Alessio, S. Roggero, A. Funaro, L. B. De Monte, L. Peruzzi, M. Geuna and F. Malavasi, CD38 molecule: Structural and biochemical analysis on human T lymphocytes, thymocytes, and plasma cells, J Immunol 145 (1990), 878-884.
2. C. M. Ausiello, F. Urbani, A. la Sala, A. Funaro and F. Malavasi, CD38 ligation induces discrete cytokine mRNA expression in human cultured lymphocytes, Eur J Immunol 25 (1995), 1477-1480.
3. C. M. Ausiello, F. Urbani, R. Lande, A. la Sala, B. Di Carlo, G. Baj, N. Surico, J. Hilgers, S. Deaglio, A. Funaro and F. Malavasi, Functional topography of discrete domains of human CD38, Tissue Antigens 56 (2000), 539-547.
4. B. V. Ayyar, S. Arora and R. O'Kennedy, Coming-of-Age of Antibodies in Cancer Therapeutics, Trends Pharmacol Sci (2016).
5. J. P. Changeux and S. J. Edelstein, Allosteric mechanisms of signal transduction, Science 308 (2005), 1424-1428.
6. A. Chillemi, G. Zaccarello, V. Quarona, M. Ferracin, C. Ghimenti, M. Massaia, A. L. Horenstein and F. Malavasi, Anti-CD38 antibody therapy: Windows of opportunity yielded by the functional characteristics of the target molecule, Mol Med 19 (2013), 99-108.
7. A. Chillemi, G. Zaccarello, V. Quarona, M. Lazzaretti, E. Martella, N. Giuliani, R. Ferracini, V. Pistoia, A. L. Horenstein and F. Malavasi, CD38 and bone marrow microenvironment, Front Biosci (Landmark Ed) 19 (2014), 152-162.
8. M. Chodorge, S. Zuger, C. Stirnimann, C. Briand, L. Jermutus, M. G. Grutter and R. R. Minter, A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency, Cell Death Differ 19 (2012), 1187-1195.
9. A. B. Cosimi, R. B. Colvin, R. C. Burton, R. H. Rubin, G. Goldstein, P. C. Kung, W. P. Hansen, F. L. Delmonico and P. S. Russell, Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts, N Engl J Med 305 (1981), 308-314.
10. Q. Cui and M. Karplus, Allostery and cooperativity revisited, Protein Sci 17 (2008), 1295-1307.
11. S. Deaglio, U. Dianzani, A. L. Horenstein, J. E. Fernandez, C. van Kooten, M. Bragardo, A. Funaro, G. Garbarino, F. Di Virgilio, J. Banchereau and F. Malavasi, Human CD38 ligand. A 120-KDA protein predominantly expressed on endothelial cells, J Immunol 156 (1996), 727-734.
12. S. Deaglio, R. Mallone, G. Baj, A. Arnulfo, N. Surico, U. Dianzani, K. Mehta and F. Malavasi, CD38/CD31, a receptor/ligand system ruling adhesion and signaling in human leukocytes, Chem Immunol 75 (2000), 99-120.
13. S. Deaglio, M. Morra, R. Mallone, C. M. Ausiello, E. Prager, G. Garbarino, U. Dianzani, H. Stockinger and F. Malavasi, Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member, J Immunol 160 (1998), 395-402.
14. S. Deaglio, M. Zubiaur, A. Gregorini, F. Bottarel, C. M. Ausiello, U. Dianzani, J. Sancho and F. Malavasi, Human CD38 and CD16 are functionally dependent and physically associated in natural killer cells, Blood 99 (2002), 2490-2498.
15. J. Deckert, M. C. Wetzel, L. M. Bartle, A. Skaletskaya, V. S. Goldmacher, F. Vallee, Q. Zhou-Liu, P. Ferrari, S. Pouzieux, C. Lahoute, C. Dumontet, A. Plesa, M. Chiron, P. Lejeune, T. Chittenden, P. U. Park and V. Blanc, SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies, Clin Cancer Res 20 (2014), 4574-4583.
16. G. Fedele, M. Di Girolamo, U. Recine, R. Palazzo, F. Urbani, A. L. Horenstein, F. Malavasi and C. M. Ausiello, CD38 ligation in peripheral blood mononuclear cells of myeloma patients induces release of protumorigenic IL-6 and impaired secretion of IFNgamma cytokines and proliferation, Mediators Inflamm 2013 (2013), 564687.
17. G. Fedele, L. Frasca, R. Palazzo, E. Ferrero, F. Malavasi and C. M. Ausiello, CD38 is expressed on human mature monocyte-derived dendritic cells and is functionally involved in CD83 expression and IL-12 induction, Eur J Immunol 34 (2004), 1342-1350.
18. E. Ferrero and F. Malavasi, The metamorphosis of a molecule: From soluble enzyme to the leukocyte receptor CD38, J Leukoc Biol 65 (1999), 151-161.
19. E. Ferrero, F. Saccucci and F. Malavasi, The human CD38 gene: Polymorphism, CpG island, and linkage to the CD157 (BST-1) gene, Immunogenetics 49 (1999), 597-604.
20. L. Frasca, G. Fedele, S. Deaglio, C. Capuano, R. Palazzo, T. Vaisitti, F. Malavasi and C. M. Ausiello, CD38 orchestrates migration, survival, and Th1 immune response of human mature dendritic cells, Blood 107 (2006), 2392-2399.
21. A. Funaro, G. C. Spagnoli, C. M. Ausiello, M. Alessio, S. Roggero, D. Delia, M. Zaccolo and F. Malavasi, Involvement of the multilineage CD38 molecule in a unique pathway of cell activation and proliferation, J Immunol 145 (1990), 2390-2396.
22. Z. G. Gao, S. K. Kim, A. P. Ijzerman and K. A. Jacobson, Allosteric modulation of the adenosine family of receptors, Mini Rev Med Chem 5 (2005), 545-553.
23. C. D. Haffner, J. D. Becherer, E. E. Boros, R. Cadilla, T. Carpenter, D. Cowan, D. N. Deaton, Y. Guo, W. Harrington, B. R. Henke, M. R. Jeune, I. Kaldor, N. Milliken, K. G. Petrov, F. Preugschat, C. Schulte, B. G. Shearer, T. Shearer, T. L. Smalley, Jr., E. L. Stewart, J. D. Stuart and J. C. Ulrich, Discovery, Synthesis, and Biological Evaluation of Thiazoloquin( az)olin(on)es as Potent CD38 Inhibitors, JMed Chem 58 (2015), 3548-3571.
24. M. Hara-Yokoyama, M. Kukimoto-Niino, K. Terasawa, S. Harumiya, K. A. Podyma-Inoue, N. Hino, K. Sakamoto, S. Itoh, N. Hashii, Y. Hiruta, N. Kawasaki, C. Mishima-Tsumagari, Y. Kaitsu, T. Matsumoto, M. Wakiyama, M. Shirouzu, T. Kasama, H. Takayanagi, N. Utsunomiya-Tate, K. Takatsu, T. Katada, Y. Hirabayashi, S. Yokoyama and M. Yanagishita, Tetrameric interaction of the ectoenzyme CD38 on the cell surface enables its catalytic and raft-association activities, Structure 20 (2012), 1585-1595.
25. A. L. Horenstein, A. Chillemi, V. Quarona, A. Zito, I. Roato, F. Morandi, D. Marimpietri, M. Bolzoni, D. Toscani, R. J. Oldham, M. Cuccioloni, A. K. Sasser, V. Pistoia, N. Giuliani and F. Malavasi, NAD(+)-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma Model, Cells 4 (2015), 520-537.
26. A. L. Horenstein, A. Chillemi, G. Zaccarello, S. Bruzzone, V. Quarona, A. Zito, S. Serra and F. Malavasi, A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes, Oncoimmunology 2 (2013), e26246.
27. A. L. Horenstein, V. Quarona, D. Toscani, F. Costa, A. Chillemi, V. Pistoia, N. Giuliani and F. Malavasi, Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates with Progression of Human Myeloma, Mol Med 22 (2016), 694-704.
28. S. Hoshino, I. Kukimoto, K. Kontani, S. Inoue, Y. Kanda, F. Malavasi and T. Katada, Mapping of the catalytic and epitopic sites of human CD38/NAD+ glycohydrolase to a functional domain in the carboxyl terminus, J Immunol 158 (1997), 741-747.
29. V. Hoyos and I. Borrello, The immunotherapy era of myeloma: Monoclonal antibodies, vaccines, and adoptive Tcell therapies, Blood 128 (2016), 1679-1687.
30. S. Inoue, K. Kontani, N. Tsujimoto, Y. Kanda, N. Hosoda, S. Hoshino, O. Hazeki and T. Katada, Protein-tyrosine phosphorylation by IgG1 subclass CD38 monoclonal antibodies is mediated through stimulation of the FcgammaII receptors in human myeloid cell lines, J Immunol 159 (1997), 5226-5232.
31. D. G. Jackson and J. I. Bell, Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation, J Immunol 144 (1990), 2811-2815.
32. H. Jiang, C. Acharya, G. An, M. Zhong, X. Feng, L. Wang, N. Dasilva, Z. Song, G. Yang, F. Adrian, L. Qiu, P. Richardson, N. C. Munshi, Y. T. Tai and K. C. Anderson, SAR650984 directly induces multiple myeloma cell death via lysosomalassociated and apoptotic pathways, which is further enhanced by pomalidomide, Leukemia 30 (2016), 399-408.
33. B. J. Kim, D. R. Park, T. S. Nam, S. H. Lee and U. H. Kim, Seminal CD38 Enhances Human Sperm Capacitation through Its Interaction with CD31, PLoS One 10 (2015), e0139110.
34. G. Kohler and C. Milstein, Continuous cultures of fused cells secreting antibody of predefined specificity, Nature 256 (1975), 495-497.
35. J. Krejcik, T. Casneuf, I. S. Nijhof, B. Verbist, J. Bald, T. Plesner, K. Syed, K. Liu, N. W. van de Donk, B. M. Weiss, T. Ahmadi, H. M. Lokhorst, T. Mutis and A. K. Sasser, Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma, Blood 128 (2016), 384-394.
36. R. Lande, F. Urbani, B. Di Carlo, G. Sconocchia, S. Deaglio, A. Funaro, F. Malavasi and C. M. Ausiello, CD38 ligation plays a direct role in the induction of IL-1beta, IL-6, and IL-10 secretion in resting human monocytes, Cell Immunol 220 (2002), 30-38.
37. H. C. Lee and R. Aarhus, Wide distribution of an enzyme that catalyzes the hydrolysis of cyclic ADP-ribose, Biochim Biophys Acta 1164 (1993), 68-74.
38. R. A. Lerner, Combinatorial antibody libraries: New advances, new immunological insights, Nat Rev Immunol 16 (2016), 498-508.
39. E. D. Levy and J. B. Pereira-Leal, Evolution and dynamics of protein interactions and networks, Curr Opin Struct Biol 18 (2008), 349-357.
40. T. Li, S. Qi, M. Unger, Y. N. Hou, Q. W. Deng, J. Liu, C. M. Lam, X. W. Wang, D. Xin, P. Zhang, F. Koch-Nolte, Q. Hao, H. Zhang, H. C. Lee and Y. J. Zhao, Immuno-targeting the multifunctional CD38 using nanobody, Sci Rep 6 (2016), 27055.
41. P. Lin, R. Owens, G. Tricot and C. S. Wilson, Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma, Am J Clin Pathol 121 (2004), 482-488.
42. Q. Liu, I. A. Kriksunov, R. Graeff, C. Munshi, H. C. Lee and Q. Hao, Crystal structure of human CD38 extracellular domain, Structure 13 (2005), 1331-1339.
43. H. M. Lokhorst, T. Plesner, J. P. Laubach, H. Nahi, P. Gimsing, M. Hansson, M. C. Minnema, U. Lassen, J. Krejcik, A. Palumbo, N. W. van de Donk, T. Ahmadi, I. Khan, C. M. Uhlar, J. Wang, A. K. Sasser, N. Losic, S. Lisby, L. Basse, N. Brun and P. G. Richardson, Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma, N Engl J Med 373 (2015), 1207-1219.
44. F. Malavasi, L. B. De Monte, A. Funaro, E. Magrini, L. D. Bonino, M. Momo, M. Mariani, A. Horenstein and P. G. Natali, Cell surface receptors and bispecific monoclonal antibodies: The link between basic science and medical oncology, Year Immunol 7 (1993), 74-80.
45. F. Malavasi, S. Deaglio, R. Damle, G. Cutrona, M. Ferrarini and N. Chiorazzi, CD38 and chronic lymphocytic leukemia: A decade later, Blood 118 (2011), 3470-3478.
46. F. Malavasi, S. Deaglio, A. Funaro, E. Ferrero, A. L. Horenstein, E. Ortolan, T. Vaisitti and S. Aydin, Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology, Physiol Rev 88 (2008), 841-886.
47. R. Mallone, S. Ferrua, M. Morra, E. Zocchi, K. Mehta, L. D. Notarangelo and F. Malavasi, Characterization of a CD38-like 78-kilodalton soluble protein released from B cell lines derived from patients with X-linked agammaglobulinemia, J Clin Invest 101 (1998), 2821-2830.
48. E. Maverakis, K. Kim, M. Shimoda, M. E. Gershwin, F. Patel, R. Wilken, S. Raychaudhuri, L. R. Ruhaak and C. B. Lebrilla, Glycans in the immune system and The Altered Glycan Theory of Autoimmunity: A critical review, J Autoimmun 57 (2015), 1-13.
49. I. Melero, W. W. Shuford, S. A. Newby, A. Aruffo, J. A. Ledbetter, K. E. Hellstrom, R. S. Mittler and L. Chen, Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors, Nat Med 3 (1997), 682-685.
50. S. C. Meuer, O. Acuto, R. E. Hussey, J. C. Hodgdon, K. A. Fitzgerald, S. F. Schlossman and E. L. Reinherz, Evidence for the T3-associated 90K heterodimer as the T-cell antigen receptor, Nature 303 (1983), 808-810.
51. S. C. Meuer, D. A. Cooper, J. C. Hodgdon, R. E. Hussey, K. A. Fitzgerald, S. F. Schlossman and E. L. Reinherz, Identification of the receptor for antigen and major histocompatibility complex on human inducer T lymphocytes, Science 222 (1983), 1239-1242.
52. S. C. Meuer, K. A. Fitzgerald, R. E. Hussey, J. C. Hodgdon, S. F. Schlossman and E. L. Reinherz, Clonotypic structures involved in antigen-specific human T cell function. Relationship to the T3 molecular complex, J Exp Med 157 (1983), 705-719.
53. F. Morandi, A. L. Horenstein, A. Chillemi, V. Quarona, S. Chiesa, A. Imperatori, S. Zanellato, L. Mortara, M. Gattorno, V. Pistoia and F. Malavasi, CD56brightCD16-NK Cells Produce Adenosine through a CD38-Mediated Pathway and Act as Regulatory Cells Inhibiting Autologous CD4+T Cell Proliferation, J Immunol 195 (2015), 965-972.
54. F. Morandi, B. Morandi, A. L. Horenstein, A. Chillemi, V. Quarona, G. Zaccarello, P. Carrega, G. Ferlazzo, M. C. Mingari, L. Moretta, V. Pistoia and F. Malavasi, A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferation, Oncotarget 6 (2015), 25602-25618.
55. M. Morra, M. Zubiaur, C. Terhorst, J. Sancho and F. Malavasi, CD38 is functionally dependent on the TCR/CD3 complex in human T cells, FASEB J 12 (1998), 581-592.
56. I. S. Nijhof, R. W. Groen, H. M. Lokhorst, B. van Kessel, A. C. Bloem, J. van Velzen, R. de Jong-Korlaar, H. Yuan, W. A. Noort, S. K. Klein, A. C. Martens, P. Doshi, K. Sasser, T. Mutis and N. W. van de Donk, Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab, Leukemia 29 (2015), 2039-2049.
57. T. Okajima, B. Reddy, T. Matsuda and K. D. Irvine, Contributions of chaperone and glycosyltransferase activities of O fucosyltransferase 1 to Notch signaling, BMC Biol 6 (2008), 1.
58. M. B. Overdijk, S. Verploegen, M. Bogels, M. van Egmond, J. J. Lammerts van Bueren, T. Mutis, R. W. Groen, E. Breij, A. C. Martens, W. K. Bleeker and P. W. Parren, Antibodymediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma, MAbs 7 (2015), 311-321.
59. G. Palade, Intracellular aspects of the process of protein synthesis, Science 189 (1975), 347-358.
60. D. M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer 12 (2012), 252-264.
61. K. S. Peggs, S. A. Quezada and J. P. Allison, Cancer immunotherapy: Co-stimulatory agonists and co-inhibitory antagonists, Clin Exp Immunol 157 (2009), 9-19.
62. N. Preyat and O. Leo, Complex role of nicotinamide adenine dinucleotide in the regulation of programmed cell death pathways, Biochem Pharmacol 101 (2016), 13-26.
63. V. Quarona, V. Ferri, A. Chillemi, M. Bolzoni, C. Mancini, G. Zaccarello, I. Roato, F. Morandi, D. Marimpietri, G. Faccani, E. Martella, V. Pistoia, N. Giuliani, A. L. Horenstein and F. Malavasi, Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche, Ann N Y Acad Sci 1335 (2015), 10-22.
64. V. Quarona, G. Zaccarello, A. Chillemi, E. Brunetti, V. K. Singh, E. Ferrero, A. Funaro, A. L. Horenstein and F. Malavasi, CD38 and CD157: A long journey from activation markers to multifunctional molecules, Cytometry B Clin Cytom 84 (2013), 207-217.
65. S. Y. Rah, J. Y. Kwak, Y. J. Chung and U. H. Kim, ADPribose/TRPM2-mediated Ca2+ signaling is essential for cytolytic degranulation and antitumor activity of natural killer cells, Sci Rep 5 (2015), 9482.
66. E. L. Reinherz, R. E. Hussey and S. F. Schlossman, A monoclonal antibody blocking human T cell function, Eur J Immunol 10 (1980), 758-762.
67. E. L. Reinherz, P. C. Kung, G. Goldstein and S. F. Schlossman, Separation of functional subsets of human T cells by a monoclonal antibody, Proc Natl Acad Sci USA 76 (1979), 4061-4065.
68. D. P. Ryan and J. M. Matthews, Protein-protein interactions in human disease, Curr Opin Struct Biol 15 (2005), 441-446.
69. F. Schweisguth, Regulation of notch signaling activity, Curr Biol 14 (2004), R129-138.
70. L. S. Swapna, S. Mahajan, A. G. de Brevern and N. Srinivasan, Comparison of tertiary structures of proteins in proteinprotein complexes with unbound forms suggests prevalence of allostery in signalling proteins, BMC Struct Biol 12 (2012), 6.
71. A. Sy and R. Z. Silkiss, Serum total IgG and IgG4 levels in thyroid eye disease, Int Med Case Rep J 9 (2016), 325-328.
72. B. C. Trauth, C. Klas, A. M. Peters, S. Matzku, P. Moller, W. Falk, K. M. Debatin and P. H. Krammer, Monoclonal antibodymediated tumor regression by induction of apoptosis, Science 245 (1989), 301-305.
73. N. W. van de Donk, M. L. Janmaat, T. Mutis, J. J. Lammerts van Bueren, T. Ahmadi, A. K. Sasser, H. M. Lokhorst and P. W. Parren, Monoclonal antibodies targeting CD38 in hematological malignancies and beyond, Immunol Rev 270 (2016), 95-112.
74. N. W. van de Donk, P. Moreau, T. Plesner, A. Palumbo, F. Gay, J. P. Laubach, F. Malavasi, H. Avet-Loiseau, M. V. Mateos, P. Sonneveld, H. M. Lokhorst and P. G. Richardson, Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma, Blood 127 (2016), 681-695.
75. M. Vidal, M. E. Cusick and A. L. Barabasi, Interactome networks and human disease, Cell 144 (2011), 986-998.
76. E. A. Zhukovsky, R. J. Morse and M. V. Maus, Bispecific antibodies and CARs: Generalized immunotherapeutics harnessing T cell redirection, Curr Opin Immunol 40 (2016), 24-35.
77. A. Zito, C. Bromuro, G. Mandili, P. Chiani, A. L. Horenstein, F. Malavasi, R. Cauda, A. Cassone and A. Torosantucci, A Murine, Bispecific Monoclonal Antibody Simultaneously Recognizing beta-Glucan andMP65 Determinants in Candida Species, PLoS One 11 (2016), e0148714.
78. L. Zitvogel, L. Galluzzi, M. J. Smyth and G. Kroemer, Mechanism of action of conventional and targeted anticancer therapies: Reinstating immunosurveillance, Immunity 39 (2013), 74-88.
79. M. Zubiaur, M. Guirado, C. Terhorst, F. Malavasi and J. Sancho, The CD3-gamma delta epsilon transducing module mediates CD38-induced protein-tyrosine kinase and mitogenactivated protein kinase activation in Jurkat T cells, J Biol Chem 274 (1999), 20633-20642.